Vasopressin Administration in Critical Care
Vasopressin should be added to norepinephrine at a fixed dose of 0.03 units/minute (up to 0.04 units/minute maximum) in vasodilatory shock refractory to initial norepinephrine therapy, never as monotherapy. 1, 2
Refractory Vasodilatory Shock (Septic Shock)
When to Initiate
- Start norepinephrine first as the primary vasopressor targeting MAP ≥65 mmHg 1
- Add vasopressin when norepinephrine requirements remain elevated despite adequate fluid resuscitation (typically when norepinephrine >0.5 mcg/kg/min based on clinical practice) 3
- Vasopressin is FDA-approved specifically for adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines 2
Dosing Protocol
- Fixed dose: 0.03 units/minute (up to 0.04 units/minute maximum) 1, 4, 1
- Never exceed 0.04 units/minute except as salvage therapy when all other vasopressors have failed 1, 4
- Never use as sole initial vasopressor - this is explicitly contraindicated 1, 4
- Dilute 20 units/mL vial with normal saline or D5W to either 0.1 units/mL or 1 unit/mL 2
- Discard unused diluted solution after 18 hours at room temperature or 24 hours refrigerated 2
Clinical Rationale
Vasopressin works independently of catecholamine receptors through V1 receptor-mediated vasoconstriction, making it effective when alpha-adrenergic receptors are downregulated in septic shock 3. The Surviving Sepsis Campaign guidelines provide weak recommendations (moderate quality evidence) for adding vasopressin to raise MAP or decrease norepinephrine dosage 1. Importantly, no mortality benefit has been demonstrated - the VASST trial showed no difference in 28-day mortality between vasopressin and norepinephrine 3.
Monitoring Requirements
- Place arterial catheter as soon as practical in all patients requiring vasopressors 4, 1
- Titrate norepinephrine to maintain MAP target while vasopressin remains at fixed dose
- Monitor for adverse effects: excessive vasoconstriction, digital/mesenteric/coronary ischemia, hyponatremia, bradycardia 2, 5
- Risk of cardiac arrest above 0.04 units/minute 5
Weaning Strategy
When norepinephrine decreases to approximately 0.2 mcg/kg/min, withdraw vasopressin in small steps according to MAP response 3. Continue monitoring for transient diabetes insipidus after discontinuation (polyuria, hypernatremia) which typically self-resolves within 24 hours 6.
Acute Variceal Hemorrhage
When to Initiate
Start vasoactive drugs immediately when variceal hemorrhage is suspected or confirmed, before diagnostic endoscopy 7. This is critical - early initiation reduces 7-day mortality (RR 0.74), improves hemostasis (RR 1.21), and decreases transfusion requirements 8.
Drug Selection
Terlipressin is preferred over vasopressin for variceal bleeding 8. Vasopressin itself is no longer recommended due to significant adverse effects including increased peripheral vascular resistance, reduced cardiac output, and coronary vasoconstriction 8.
If terlipressin unavailable, alternatives include:
- Terlipressin: 2 mg IV bolus, then 1-2 mg IV every 4-6 hours 8
- Octreotide: 50 mcg IV bolus, then 50 mcg/hour infusion 8
- Somatostatin: 250 mcg IV bolus, then 250 mcg/hour infusion 8
Duration
Continue for 2-5 days after initial endoscopic hemostasis to prevent early rebleeding 8, 7. Stop immediately if endoscopy reveals non-variceal bleeding 7.
Critical Caveats
- Terlipressin is the only vasoactive drug proven to reduce bleeding-related mortality (RR 0.66) 8
- Monitor for hyponatremia and myocardial ischemia with terlipressin 8
- Combine with prophylactic antibiotics (ceftriaxone 1g IV daily) and endoscopic variceal ligation 8
Central Diabetes Insipidus
Acute Postoperative Management
For acute central DI with hypovolemic shock (particularly post-neurosurgery), a dilute vasopressin bolus protocol can be used as bridge therapy: 1 unit vasopressin in 1 liter of 0.45% normal saline, given in boluses calculated as (urine output - 100 mL) 9.
Standard Treatment
Desmopressin (DDAVP) is the definitive treatment for central diabetes insipidus, not vasopressin 9, 10. Vasopressin infusion for hemodynamic support can mask or complicate DI diagnosis through V2 receptor activation causing water reabsorption 5, 10.
Post-Vasopressin Monitoring
Watch for transient DI after discontinuing vasopressin infusion used for shock management 6. Classic findings within 12-24 hours of stopping vasopressin:
- Polyuria (>3 L/day, up to 1 L/hour)
- Hypernatremia (sodium increase >10 mmol/L)
- Dilute urine (low specific gravity)
- Typically self-resolves within 24 hours without intervention 6
Key Distinction
The term "vasopressin deficiency" is now preferred over "central diabetes insipidus" to avoid confusion with diabetes mellitus 10. Treatment focuses on desmopressin replacement, not vasopressin infusion.
Common Pitfalls to Avoid
- Never start vasopressin as monotherapy in any shock state 1, 4
- Never exceed 0.04 units/minute except as last resort - risk of cardiac arrest 4, 5
- Do not use vasopressin for variceal bleeding - use terlipressin or alternatives 8
- Do not confuse vasopressin (for shock) with desmopressin (for DI) - different indications and mechanisms 9, 10
- Recognize transient DI after vasopressin withdrawal - usually benign and self-limited 6
- Avoid in cardiogenic shock without cardiac output monitoring - can worsen cardiac function 3, 2